Sign In
Buy CTLT
$63.49
+0 (+0%)
At Close: Mar 14, 2025
Catalent (CTLT) Reports Q1 Loss, Lags Revenue Estimates
09:25am, Tuesday, 05'th Nov 2024
Catalent (CTLT) came out with a quarterly loss of $0.13 per share versus the Zacks Consensus Estimate of $0.11. This compares to loss of $0.10 per share a year ago.
Catalent misses Q1 revenue estimates ahead of $16.5 bln deal close with Novo Holdings
08:25am, Tuesday, 05'th Nov 2024
Contract drug manufacturer Catalent , which is in the process of being acquired by Novo Holdings, posted a surprise first-quarter loss and revenue below Wall Street estimates on Tuesday.
EU antitrust regulators to decide on Novo's Catalent buy by Dec. 6
03:01am, Monday, 04'th Nov 2024
EU antitrust regulators will decide by Dec. 6 whether to clear Novo Holdings' acquisition of contract drug manufacturer Catalent , according to a filing on the European Commission website on Monday.
CTLT Stock Falls as Potential Hindrance to NVO Buyout Deal Increases
12:10pm, Thursday, 24'th Oct 2024
Catalent stock faces uncertainty as several pharma companies voice concern about potential limited competition following the acquisition, especially in weight-loss drug manufacturing.
Roche comes out against clearing takeover of drug manufacturer Catalent
04:41am, Wednesday, 23'rd Oct 2024
The CEO of pharmaceuticals giant Roche has urged authorities to block the takeover of contract drug manufacturer Catalent by Novo Nordisk's controlling shareholder, citing harm to industry peers.
Catalent CEO to remain in charge of contract drugmaker after Novo Holdings' buyout
07:31am, Monday, 21'st Oct 2024
Catalent president and CEO Alessandro Maselli said on Monday he will stay on as the contract drugmaker's chief after it is acquired by Novo Holdings, the controlling shareholder of weight-loss drug ma
Consumer groups ask FTC to block Novo Holdings-Catalent deal
02:03pm, Thursday, 17'th Oct 2024
Five U.S. consumer groups and two large labor unions urged the U.S. Federal Trade Commission on Thursday to block Novo Nordisk's controlling shareholder from acquiring contract drug manufacturer Catal
Catalent Stock Flat Following the Sell Agreement With Ardena
02:16pm, Wednesday, 16'th Oct 2024
CTLT announces an agreement to sell its oral solids development and manufacturing facility in Somerset to Ardena.
Catalent to sell New Jersey facility
06:40am, Monday, 14'th Oct 2024
Catalent has agreed to sell its oral drug development and small-scale manufacturing facility in Somerset, New Jersey to private contract drug manufacturer Ardena, the companies said on Monday.
Catalent Signs Agreement to Sell Somerset, NJ Oral Solids Facility
06:00am, Monday, 14'th Oct 2024
SOMERSET, N.J.--(BUSINESS WIRE)--Catalent, Inc. (NYSE: CTLT), the leader in enabling the development and supply of better treatments for patients worldwide, announced today that it has entered into a
Ardena Signs Agreement to Expand US Footprint with the Acquisition of Advanced Drug Product Manufacturing Facility from Catalent
06:00am, Monday, 14'th Oct 2024
Ghent, Belgium, Oct. 14, 2024 (GLOBE NEWSWIRE) -- Ardena, a specialist pharmaceutical Contract Development and Manufacturing Organisation (CDMO) with GMP facilities in Belgium, Spain, the Netherlands
US Senator Warren calls for scrutiny of Novo Holdings' Catalent deal
08:03am, Thursday, 10'th Oct 2024
U.S. Senator Elizabeth Warren has asked antitrust regulators to closely scrutinize a $16.5 billion deal in which Novo Nordisk's controlling shareholder would acquire contract drug manufacturer Catalen
More Interest Rate Cuts Ahead: 5 Growth Stocks to Benefit
03:01pm, Thursday, 03'rd Oct 2024
These fives stocks have strong growth potential for the rest of 2024. These are: APP, DUOL, PARAA, TWLO, CTLT.
TAK or CTLT: Which Is the Better Value Stock Right Now?
12:46pm, Thursday, 03'rd Oct 2024
Investors interested in stocks from the Medical - Drugs sector have probably already heard of Takeda Pharmaceutical Co. (TAK) and Catalent (CTLT). But which of these two stocks is more attractive to v
Catalent (CTLT) Upgraded to Strong Buy: Here's What You Should Know
01:00pm, Thursday, 12'th Sep 2024
Catalent (CTLT) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
